TWENTYEIGHT-SEVEN

Our therapeutic goal in cancer is to develop small-molecule drugs against nucleic acid regulators which in turn can impact multiple hallmarks of cancer. New cancer hallmarks being considered, such as aberrant RNA splicing, represent our mission to forge new paths to develop novel therapies that are intended to be more robust and durable than the current standard of care... Our leadership understands the courage needed to commit to the tough journey of drug discovery. As experienced and dedicated explorers, we understand the trust, respect, and teamwork needed to pursue the unknown... Our Therapies Restore Balance. We are explorers leading the revolution in RNA drug discovery to develop an entirely new class of therapies. We are identifying the chemical motifs to potently and selectively modulate RNA regulatory networks to treat the most challenging diseases.

Also known as: Twentyeight-Seven, Inc.

Primary location: Watertown United States